Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.55 |
| ▸ | CA2 | P00918 | 6/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | THRA | P10827 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7768642 | 1.00 | CA1 (0.55) | CA1CA2CA4CA12CA9 | |
| SCHEMBL1197762 | 1.00 | CA1 (0.55) | CA1CA2CA4CA12CA9 | |
| SCHEMBL8772754 | 1.00 | CA1 (0.55) | CA1CA2CA4CA12CA9 | |
| SCHEMBL4275036 | 0.99 | S1PR1 (0.55) | CA1CA2CA4CA12CA9 | |
| SCHEMBL7511976 | 0.96 | ICMT (0.54) | CA1CA2CA4CA12CA9 | |
| Butilfenin SCHEMBL487062 | 0.88 | POLB (0.62) | CA1CA2CA12CA9S1PR1 | |
| SCHEMBL15499792 | 0.82 | CA1 (0.75) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13523700 | 0.81 | CA1 (0.66) | CA1CA2CA4CA12CA9 | |
| SCHEMBL13523716 | 0.81 | CA1 (0.59) | CA1CA2CA4CA12CA9 | |
| SCHEMBL6047697 | 0.80 | CA1 (0.64) | CA1CA2CA4CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605146-B2 | Process for producing an amide compound | NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) | 2009-10-20 | — | — | US | claimed |
| EP-1199312-A2 | Process for producing an amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-04-24 | — | — | EP | claimed |
| EP-0603403-B1 | NOVEL CHELATING AGENT, COMPLEX COMPOUND COMPOSED OF SAID AGENT AND METALLIC ATOM, AND DIAGNOSTIC AGENT CONTAINING SAID COMPOUND | GREEN CROSS CORP (JP) | 1997-10-15 | — | — | EP | claimed |
| US-5453264-A | Chelating agent, complex compound of said chelating agent and metallic atom, and diagnostic agent comprising same | THE GREEN CROSS CORPORATION (JP) | 1995-09-26 | — | — | US | claimed |
| EP-0603403-A1 | NOVEL CHELATING AGENT, COMPLEX COMPOUND COMPOSED OF SAID AGENT AND METALLIC ATOM, AND DIAGNOSTIC AGENT CONTAINING SAID COMPOUND | THE GREEN CROSS CORPORATION (JP) | 1994-06-29 | — | — | EP | claimed |
| US-7605146-B2 | Process for producing an amide compound | NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) | 2009-10-20 | — | — | US | disclosed |
| EP-1199312-B1 | Process for producing an amide compound | SUMITOMO CHEMICAL CO (JP) | 2004-07-21 | — | — | EP | disclosed |
| US-20020077456-A1 | Process for producing an amide compound | NIHON MEDI-PHYSICS COMPANY, LIMITED (JP) | 2002-06-20 | — | — | US | disclosed |
| EP-1199312-A2 | Process for producing an amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-04-24 | — | — | EP | disclosed |
| EP-0603403-B2 | NOVEL CHELATING AGENT, COMPLEX COMPOUND COMPOSED OF SAID AGENT AND METALLIC ATOM, AND DIAGNOSTIC AGENT CONTAINING SAID COMPOUND | WELFIDE CORP (JP) | 2001-06-27 | — | — | EP | disclosed |
| EP-0603403-B1 | NOVEL CHELATING AGENT, COMPLEX COMPOUND COMPOSED OF SAID AGENT AND METALLIC ATOM, AND DIAGNOSTIC AGENT CONTAINING SAID COMPOUND | GREEN CROSS CORP (JP) | 1997-10-15 | — | — | EP | disclosed |
| US-5575986-A | Chelating agent, complex compound of said chelating agent and metallic atom, and diagnostic agent comprising same | THE GREEN CROSS CORPORATION (JP) | 1996-11-19 | — | — | US | disclosed |
| US-5453264-A | Chelating agent, complex compound of said chelating agent and metallic atom, and diagnostic agent comprising same | THE GREEN CROSS CORPORATION (JP) | 1995-09-26 | — | — | US | disclosed |
| EP-0603403-A1 | NOVEL CHELATING AGENT, COMPLEX COMPOUND COMPOSED OF SAID AGENT AND METALLIC ATOM, AND DIAGNOSTIC AGENT CONTAINING SAID COMPOUND | THE GREEN CROSS CORPORATION (JP) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077456-A1 | Process for producing an amide compound | NAAA, ACMSD, CPS1 | CA1 286/4885CA2 1391/4885CA4 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.